Table 1 Summary characteristics of the 15 IBSM individuals used for model development
Characteristic | n (%) |
|---|---|
Gender | |
Male | 11 (73%) |
Female | 4 (27%) |
Age | |
18–24 | 9 (60%) |
25–29 | 4 (27%) |
30–55 | 2 (13%) |
Weight (kg) | |
50–69 | 4 (27%) |
70–89 | 9 (60%) |
90–110 | 2 (13%) |
Pre-treatment peak parasitaemia (parasites/mL) | |
0–9999 | 5 (33%) |
10,000–19,999 | 5 (33%) |
20,000–29,999 | 3 (20%) |
30,000–61,357 | 2 (13%) |
Pre-treatment peak PfHRP2 (pg/mL) | |
0–299 | 5 (33%) |
300–599 | 3 (20%) |
600–899 | 4 (27%) |
900–2163 | 3 (20%) |
Anti-malarial drug administered at day 7 post inoculation | |
200 mg artefenomel + 50 mg DSM265 | 3 (20%) |
480 mg piperaquine | 5 (33%) |
400 mg DSM265 | 7 (47%) |